Skip to content
The Nexus
DossierENTITY

PRMT5 inhibitor

Coverage of PRMT5 inhibitor in the Nexus archive.

Earliest in view: Jun 11 · 12:05 UTCMost recent: Jun 11 · 12:05 UTC
Co-mentioned in this coverage
Tango Therapeuticsorganization1Revolution Medicinesorganization1Bristol Myers Squibborganization1pancreatic cancertopic1synthetic lethalitytopic1pan-RAS inhibitortopic1
Recent coverage
  • HEALTHJun 11 · 12:05 UTCSTAT NEWS
    STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&A

    A clinical trial showed improved outcomes for pancreatic cancer patients using a combination of Tango Therapeutics' PRMT5 inhibitor and Revolution Medicines' pan-RAS inhibitor. The article speculates on potential biotech mergers and acquisitions involving companies like Revolution Medicines, Tango Therapeutics, and Bristol Myers Squibb.